,7 Although higher PD-L1 TPS is associated with better treatment outcomes with ICIs, approximately 30% of patients with NSCLC experience disease progression after first-line pembrolizumab treatment, even with PD-L1 TPS more than or equal to 50%.6 The gene discussed is CD274; the disease is non-small cell lung carcinoma.